US › Healthcare

Protagenic Therapeutics (PTIX)

US · Healthcare · Biotechnology

$0.22+20.78%

Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue

Revenue YoY

+100.0%

Net profit

$2.2M

Profit YoY

+242.3%

EPS

$-0.47

Key statistics

Market cap

$325,837

Forward P/E

0.0

P/B

3.35

Book value

$-1.24

EPS (TTM)

$-13.13

52-week high

$6.20

52-week low

$0.13

50-day MA

$0.37

200-day MA

$0.94

Beta

0.38

Analyst view

Analysts rate Protagenic Therapeutics a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.00.

Shareholding

Insiders

3.84%

Institutions

4.64%

Largest institutional holders

Fund	Stake
DRW Securities, LLC	2.31%
United Financial Planning Group LLC	0.00%
Morgan Stanley - Brokerage Accounts	0.00%
Geode Capital Management, LLC	0.00%
Tower Research Capital LLC	0.00%
HARBOR INVESTMENT ADVISORY, LLC	0.00%
Advisor Group Holdings, Inc.	0.00%
CoreCap Advisors, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Protagenic Therapeutics — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.